---
title: "ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 | IBRX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286980919.md"
description: "ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 | IBRX Stock News"
datetime: "2026-05-19T16:30:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286980919.md)
  - [en](https://longbridge.com/en/news/286980919.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286980919.md)
---

# ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 | IBRX Stock News

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 | IBRX Stock News

### Related Stocks

- [IBRX.US](https://longbridge.com/en/quote/IBRX.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership](https://longbridge.com/en/news/286787574.md)
- [ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory](https://longbridge.com/en/news/286821171.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)